This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Amyl Therapeutics


Amyl Therapeutics develops a novel therapeutic platform of therapeutics aiming at treating and curing diseases caused by amyloid fibrils. Our initial indications are the various forms of systemic amyloidosis and we generated very promising pre clinical data. We are well financed and supported by our shareholders and we prepare a series B with closing Q3 2023 Key differentiators: Unique platform with pleiotropic mode of action Solid nonclinical POC including in human tissues Ready to enter clinical development in AL amyloidosis Upside potential is neurodegenerative diseases, with compelling initial results Very experienced management team Solid support by current shareholders Huge market and deal potential Limited investment for rapid and very substantial short term return